CYTK
Price
$32.43
Change
-$0.30 (-0.92%)
Updated
Jun 20 closing price
Capitalization
3.87B
39 days until earnings call
NAGE
Price
$13.44
Change
-$0.34 (-2.47%)
Updated
Jun 20 closing price
Capitalization
1.06B
45 days until earnings call
Interact to see
Advertisement

CYTK vs NAGE

Header iconCYTK vs NAGE Comparison
Open Charts CYTK vs NAGEBanner chart's image
Cytokinetics
Price$32.43
Change-$0.30 (-0.92%)
Volume$2.41M
Capitalization3.87B
Niagen Bioscience
Price$13.44
Change-$0.34 (-2.47%)
Volume$956.66K
Capitalization1.06B
CYTK vs NAGE Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. NAGE commentary
Jun 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and NAGE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 22, 2025
Stock price -- (CYTK: $32.43 vs. NAGE: $13.44)
Brand notoriety: CYTK and NAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 129% vs. NAGE: 107%
Market capitalization -- CYTK: $3.87B vs. NAGE: $1.06B
CYTK [@Biotechnology] is valued at $3.87B. NAGE’s [@Biotechnology] market capitalization is $1.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $333.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.36B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileNAGE’s FA Score has 1 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • NAGE’s FA Score: 1 green, 4 red.
According to our system of comparison, NAGE is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 6 TA indicator(s) are bullish while NAGE’s TA Score has 2 bullish TA indicator(s).

  • CYTK’s TA Score: 6 bullish, 2 bearish.
  • NAGE’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than NAGE.

Price Growth

CYTK (@Biotechnology) experienced а -5.67% price change this week, while NAGE (@Biotechnology) price change was -1.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.57%. For the same industry, the average monthly price growth was +27.78%, and the average quarterly price growth was +14.34%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

NAGE is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+9.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($3.87B) has a higher market cap than NAGE($1.06B). NAGE YTD gains are higher at: 153.346 vs. CYTK (-31.059). NAGE has higher annual earnings (EBITDA): 14.7M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. NAGE (55.5M). NAGE has less debt than CYTK: NAGE (3.52M) vs CYTK (791M). NAGE has higher revenues than CYTK: NAGE (108M) vs CYTK (19.2M).
CYTKNAGECYTK / NAGE
Capitalization3.87B1.06B366%
EBITDA-513.62M14.7M-3,494%
Gain YTD-31.059153.346-20%
P/E RatioN/A74.67-
Revenue19.2M108M18%
Total Cash938M55.5M1,690%
Total Debt791M3.52M22,446%
FUNDAMENTALS RATINGS
CYTK vs NAGE: Fundamental Ratings
CYTK
NAGE
OUTLOOK RATING
1..100
2789
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
8561
SMR RATING
1..100
10029
PRICE GROWTH RATING
1..100
6434
P/E GROWTH RATING
1..100
198
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NAGE's Valuation (85) in the Chemicals Specialty industry is in the same range as CYTK (100) in the Biotechnology industry. This means that NAGE’s stock grew similarly to CYTK’s over the last 12 months.

NAGE's Profit vs Risk Rating (61) in the Chemicals Specialty industry is in the same range as CYTK (85) in the Biotechnology industry. This means that NAGE’s stock grew similarly to CYTK’s over the last 12 months.

NAGE's SMR Rating (29) in the Chemicals Specialty industry is significantly better than the same rating for CYTK (100) in the Biotechnology industry. This means that NAGE’s stock grew significantly faster than CYTK’s over the last 12 months.

NAGE's Price Growth Rating (34) in the Chemicals Specialty industry is in the same range as CYTK (64) in the Biotechnology industry. This means that NAGE’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for NAGE (98) in the Chemicals Specialty industry. This means that CYTK’s stock grew significantly faster than NAGE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKNAGE
RSI
ODDS (%)
Bullish Trend 5 days ago
81%
Bearish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
N/A
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SQQQ22.830.33
+1.47%
ProShares UltraPro Short QQQ
IMCV74.550.31
+0.42%
iShares Morningstar Mid-Cap Value ETF
BSMW24.460.05
+0.18%
Invesco BulletShares 2032 Muncpl Bd ETF
SABA9.03N/A
N/A
Saba Capital Income & Opportunities Fund II
ILOW40.44-0.19
-0.47%
AB Active ETFs Inc.

NAGE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAGE has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NAGE jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAGE
1D Price
Change %
NAGE100%
-2.47%
AXON - NAGE
43%
Loosely correlated
+0.85%
MDGL - NAGE
41%
Loosely correlated
+1.10%
FHTX - NAGE
35%
Loosely correlated
-0.63%
ORMP - NAGE
35%
Loosely correlated
-0.93%
AMRN - NAGE
35%
Loosely correlated
-5.93%
More